SCHEMBL413665

SCHEMBL413665

Cc1cccc(-c2nn3c(c2-c2ccnc4cc(C(=O)N(C)CCN(C)C)ccc24)CCC3)n1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 20/20 0.70
MAPK14 Q16539 5/20 0.65
THRB P10828 4/20 0.65
GAK O14976 1/20 0.65
RIPK2 O43353 1/20 0.65
MAP4K4 O95819 1/20 0.65
KDR P35968 1/20 0.65
ACVR1B P36896 1/20 0.65
TGFBR2 P37173 1/20 0.65
CSNK1A1 P48729 1/20 0.65
CSNK1D P48730 1/20 0.65
CSNK1E P49674 1/20 0.65
TGFB2 P61812 1/20 0.65
MINK1 Q8N4C8 1/20 0.65
COQ8A Q8NI60 1/20 0.65
TNIK Q9UKE5 1/20 0.65
RIPK3 Q9Y572 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5232930 0.87 TGFBR1 (0.70) TGFBR1MAPK14THRBGAKRIPK2
SCHEMBL415080 0.87 TGFBR1 (0.76) TGFBR1MAPK14THRBGAKRIPK2
SCHEMBL415073 0.87 TGFBR1 (0.63) TGFBR1MAPK14THRBGAKRIPK2
SCHEMBL413647 0.87 TGFBR1 (0.82) TGFBR1MAPK14THRBGAKRIPK2
SCHEMBL3360014 0.86 TGFBR1 (0.87) TGFBR1MAPK14THRBGAKRIPK2
SCHEMBL6101234 0.84 TGFBR1 (0.75) TGFBR1MAPK14THRBGAKRIPK2
SCHEMBL410442 0.84 TGFBR1 (0.88) TGFBR1MAPK14THRBGAKRIPK2
SCHEMBL409548 0.84 TGFBR1 (0.68) TGFBR1MAPK14THRBGAKRIPK2
SCHEMBL6099961 0.84 TGFBR1 (0.68) TGFBR1MAPK14THRBGAKRIPK2
SCHEMBL413269 0.82 TGFBR1 (0.79) TGFBR1MAPK14THRBGAKRIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040106604-A1 Novel pyrrole derivatives as pharmaceutical agents ELI LILLY AND COMPANY 2004-06-03 US claimed
WO-2012138945-A1 METHODS OF TREATING SCHIZOPHRENIA WITH PYRAZOLE DERIVATIVE INHIBITORS OF TGF - BETA AESTUS THERAPEUTICS, INC. (US) 2012-10-11 WO disclosed
US-20120021519-A1 EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) 2012-01-26 US disclosed
US-7087626-B2 Pyrrole derivatives as pharmaceutical agents ELI LILLY AND COMPANY (US) 2006-08-08 US disclosed
US-20040106604-A1 Novel pyrrole derivatives as pharmaceutical agents ELI LILLY AND COMPANY 2004-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106604-A1 Novel pyrrole derivatives as pharmaceutical agents TGFBR1, SMAD3, TGFBR2 TGFBR1 1/4885MAPK14 546/4885THRB 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.